Prof Hope Rugo speaks to ecancer about the management of HER2-low breast cancer patients.

HER2 detection tests can only tell if a patient is HER positive or negative but they don't detect the range of HER2 expression in a patient which Prof Rugo says is important to know when choosing the best treatment option for the patient.

Prof Rugo explains that there are new protein assays that can help detect the expression much better and that is something to look forward to in the near future.

She further talks about all the studies regarding ultra-low HER2-positive breast cancer and how they can be practice-changing.